Frontlight ResearchEarly access
Spinal muscular atrophy trials in South Korea
2 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
- Where
- Seoul
- Age
- 15 years to 60 years
- People
- 90 worldwide
- Run by
- Biogen
See details and how to joinNCT07444476 - No phaseTaking peopleRegistry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
- Where
- Daegu, Seongnam-si, Seoul, Yangsan, Yongin-si
- People
- 700 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04174157